Japan Central Nervous System Therapeutic Market Size, Share, and COVID-19 Impact Analysis, By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Disease, CNS Cancer, and Others), By Drug Class (Antidepressants, Antipsychotics, Antiepileptics (AEDs), Dopaminergic Agents, Neuroprotective Agents, Immunomodulators, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Japan Central Nervous System Therapeutic Market Insights, Industry Trend, Forecasts to 2035

Japan Central Nervous System Therapeutic Market Size Insights Forecasts to 2035

• The Japan Central Nervous System Therapeutic Market Size Was Estimated at USD 5421.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.4% from 2025 to 2035
• The Japan Central Nervous System Therapeutic Market Size is Expected to Reach USD 14563.7 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Japan Central Nervous System Therapeutic Market Size is anticipated to reach USD 14563.7 million by 2035, growing at a CAGR of 9.4% from 2025 to 2035. The Japan central nervous system therapeutic market is increasing with an aging population, more Alzheimer's and Parkinson's cases, and greater awareness of mental health. Technological improvement in R&D continues to fuel demand for successful treatments for neurological and psychiatric disorders.

Market Overview

The Japan central nervous system therapeutic market refers to medications and treatments intended to prevent, treat, or alter neurological and psychiatric conditions, from Parkinson and Alzheimer to depression, epilepsy, stroke, and CNS cancers. These therapies are administered through pharmacological ( Oral, Injectable, Transdermal) and Non pharmacological routes. Strengths are premium medical R&D facilities, innovative biotech uptake, and extensive coverage under Japanese national health insurance. Growth opportunities are disease- modifying therapy for neurodegenerative disorders, regenerative medicine, individualized strategies, telehealth and CNS oncology drug discovery. Market demand is driven by Japan rapid aging population, increasing incidence of neurodegenerative and mental health disorders, greater diagnostic awareness, and growing digital health access. Government efforts, such as the Sakigake advance designation, public-private councils to draw in VC and overseas money, startup subsidies, fiscal incentives, conditional prior approval systems, and clinical trial reforms, are hastening innovation, lessening approval lag, and making Japan more competitive in CNS drug discovery.

Report Coverage

This research report categorizes the market for the Japan central nervous system therapeutic market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan central nervous system therapeutic market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan central nervous system therapeutic market.

Driving Factors

The Japan central nervous system therapeutic market is fueled by its rapidly aging population, which drives the increasing incidence of neurodegenerative and psychiatric illnesses like Alzheimer and Parkinson. Public recognition, early diagnosis capacity, and advancements in neuroimaging and biomarkers further increase demand. Moreover, deep R&D spending, the emergence of new therapies such as gene and stem cell therapies, and encouragement by governments in the form of advanced approval and memory loss funding drive CNS therapeutic growth in the pharmaceutical and biotechnology industries.

Restraining Factors

The Japan central nervous system therapeutic market is confronted by limitations like expensive drug development, intricate clinical trials, and long approval times. Further, poor treatment efficacy for some neurodegenerative diseases and fear of side effects hampers wider adoption and market growth.

Market Segmentation

The Japan central nervous system therapeutic market share is classified into disease, drug class, and distribution channel.

• The neurodegenerative diseases segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan central nervous system therapeutic market is segmented by disease into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, CNS cancer, and others. Among these, the neurodegenerative diseases segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the rapidly aging population of the country, which raises the prevalence of conditions such as Alzheimer's and Parkinson's. These chronic and progressive conditions necessitate ongoing treatment, fueling high demand for new therapies, specialized care, and heavy investment in research and development.

• The antidepressants segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan central nervous system therapeutic market is segmented by drug class into antidepressants, antipsychotics, antiepileptics (AEDs), dopaminergic agents, neuroprotective agents, immunomodulators, and others. Among these, the antidepressants segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is owing to the nations important depression and anxiety prevalence, particularly among its elderly population. Growing mental health awareness, timely diagnosis, and high government support for psychiatric treatment further compel demand, with antidepressants being the most valuable drug class in this therapeutic category.

• The hospital pharmacy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan central nervous system therapeutic market is segmented by distribution channel into hospital pharmacy, retail pharmacy, and others. Among these, the hospital pharmacy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to specialized acute and complex care needs, patients tend to initiate CNS treatments in hospital facilities that have greater diagnostics, constant monitoring, and clinician supervision. Hospital pharmacy channels thus become critical for initial prescriptions and management of nervous and mental disorders.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan central nervous system therapeutic market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Otsuka Pharmaceuticals
• AstraZeneca
• Eisai Co., Ltd.
• Merck & Co.
• Astellas Pharma Inc.
• Novartis
• Biogen
• Bristol Myers Squibb
• Shionogi & Co.
• Takeda
• AbbVie
• Eli Lilly
• Teva Pharmaceutical Industries
• Others

Recent Developments:

• In September 2023, Eisai Co., Ltd. and Biogen Inc. announced Japan’s approval of LEQEMBI®, an intravenous anti-amyloid-beta (Aβ) monoclonal antibody, for treating mild cognitive impairment and early Alzheimer’s disease. LEQEMBI is the first approved therapy proven to slow disease progression by targeting and removing toxic Aβ protofibrils responsible for cognitive and functional decline.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan central nervous system therapeutic market based on the below-mentioned segments:

Japan Central Nervous System Therapeutic Market, By Disease

• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Infectious Diseases
• CNS Cancer
• Others

Japan Central Nervous System Therapeutic Market, By Drug Class

• Antidepressants
• Antipsychotics
• Antiepileptics (AEDs)
• Dopaminergic Agents
• Neuroprotective Agents
• Immunomodulators
• Others

Japan Central Nervous System Therapeutic Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others